2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Hodgkin Disease
80
Lymphoma
35
Lymphoma, Large-Cell, Anaplastic
26
Hematologic Diseases
21
Recurrence
18
Lymphoma, Non-Hodgkin
17
Lymphoma, T-Cell, Peripheral
14
Lymphoma, T-Cell, Cutaneous
13
Lymphoma, T-Cell
13
Lymphoma, Large B-Cell, Diffuse
10
Mycosis Fungoides
9
Sezary Syndrome
5
Neoplasms
5
Lymphoma, B-Cell
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphomatoid Papulosis
4
Lymphoma, Primary Cutaneous Anaplastic Large Cell
4
Lymphatic Diseases
4
Leukemia, Myeloid, Acute
4
Immunoblastic Lymphadenopathy
4
Enteropathy-Associated T-Cell Lymphoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms, Germ Cell and Embryonal
3
Lymphoma, Follicular
3
Leukemia
3
Dendritic Cell Sarcoma, Interdigitating
3
Testicular Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms by Histologic Type
2
Myelodysplastic Syndromes
2
Interventions
pembrolizumab
189
Cisplatin
47
Paclitaxel
45
Carboplatin
44
lenvatinib
31
Docetaxel
23
Pemetrexed
21
Fluorouracil
20
Capecitabine
17
Gemcitabine
15
Oxaliplatin
14
Saline Solution
13
Albumin-Bound Paclitaxel
11
130-nm albumin-bound paclitaxel
10
epacadostat
9
Leucovorin
9
Cetuximab
9
olaparib
7
Irinotecan
7
Bevacizumab
7
Etoposide
6
enzalutamide
5
durvalumab
5
belzutifan
5
Nivolumab
5
Dexamethasone
5
Surgical Procedures, Operative
4
Radiotherapy
4
trifluridine tipiracil drug combination
3
spartalizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Brentuximab Vedotin
×
Clear all
NCT02684292
2026-02-18
MK-3475-204
Merck Sharp & Dohme LLC
Phase 3
Completed
304 enrolled
1 FDA